Puma Biotechnology Advances Cancer Pipeline with Two Phase II Trials for Alisertib
核心洞察
Puma Biotechnology has initiated two Phase II clinical trials for alisertib, a selective aurora kinase A (搜索) inhibitor, targeting small cell lung cancer (搜索) and breast cancer (搜索) patients.
The ALISCA-Lung1 trial launched in February 2024 evaluates alisertib monotherapy for extensive-stage small cell lung cancer (搜索) treatment.
The ALISCA-Breast1 trial began in November 2024, testing alisertib combined with endocrine therapy for HER2-negative, HR-positive metastatic breast cancer (搜索).
Puma Biotechnology has launched two Phase II clinical trials for alisertib, marking a significant expansion of the company's oncology pipeline beyond its established NERLYNX franchise. The biopharmaceutical company is evaluating the selective aurora kinase A (搜索) inhibitor in both small cell lung cancer (搜索) and breast cancer (搜索) indications.
Clinical Development Program
In February 2024, Puma initiated ALISCA-Lung1, a Phase II clinical trial evaluating alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer (搜索). The company followed this with the launch of ALISCA-Breast1 in November 2024, a Phase II trial testing alisertib in combination with endocrine therapy for patients with HER2-negative, HR-positive metastatic breast cancer (搜索).
Alisertib is a selective, small molecule, orally administered inhibitor of aurora kinase A (搜索), an enzyme that plays a critical role in cell division. Puma obtained exclusive development and commercialization rights to the anti-cancer drug through a license agreement executed in September 2022.
Strategic Focus Areas
The company has strategically focused alisertib development on small cell lung cancer (搜索) and breast cancer (搜索), two areas with significant therapeutic challenges. Small cell lung cancer represents a particularly aggressive form of lung cancer with limited treatment options, while HER2-negative, HR-positive metastatic breast cancer affects a substantial patient population requiring effective therapeutic interventions.
Established Portfolio
Puma's clinical advancement of alisertib builds upon its established presence in breast cancer (搜索) treatment through NERLYNX (neratinib). The FDA approved NERLYNX in 2017 for extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. In February 2020, the agency expanded approval to include combination treatment with capecitabine for advanced or metastatic HER2-positive breast cancer (搜索) patients who have received two or more prior anti-HER2-based regimens.
The European Commission granted marketing authorization for NERLYNX in 2018 for extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer (搜索) who are less than one year from completion of prior adjuvant trastuzumab-based therapy.
Pipeline Expansion
The dual Phase II trial approach for alisertib demonstrates Puma's commitment to expanding its oncology portfolio into new therapeutic areas while leveraging its expertise in cancer drug development. The company's focus on both monotherapy and combination approaches reflects current oncology development strategies aimed at optimizing therapeutic efficacy across different patient populations.